ArticleCureus2024
A Case of Resectable Single-Nodule Intrahepatic Bile Duct Adenoma.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 70-year-old man was incidentally diagnosed with a single hepatic mass lesion in his right hepatic lobe during a computed tomography scan. The lesion exhibited consistent enhancement with contrast agents on computed tomography (CT), magnetic resonance imaging (MRI), and hepatic arterial angiography. While a definitive diagnosis could not be made preoperatively, the lesion was surgically resected due to its slight enlargement over two months, suggesting a potential malignancy. Pathological examination revealed the lesion to be a bile duct adenoma (BDA). The BDA was characterized by dense proliferative small gland cavities containing several to dozens of cells. Immunohistochemical staining showed positive CK7 and negative p53. The patient remains alive and free of recurrence five years after hepatectomy. Although BDAs are rare benign hepatic tumors, they carry a risk of harboring or developing malignant tissue, such as cholangiocarcinoma. Therefore, BDAs or lesions suspicious of BDA should be surgically resected or closely monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.